信达生物(01801)股东将股票存入香港上海汇丰银行 存仓市值45.98亿港元

Group 1 - The core viewpoint of the article highlights that Cinda Biologics has deposited shares worth HKD 45.98 billion into HSBC, representing 3.31% of its market value [1] - UBS has reported that six new products from Cinda Biologics and a new indication for its drug Sintilimab have been included in the latest version of the National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug List for 2025 [1] - Cinda Biologics has officially been included in the Hang Seng Index, and UBS maintains a "Buy" rating with a target price of HKD 137.4 [1]